F2G Receives the US FDA’s Breakthrough Therapy Designation for Olorofim

Shots:

• The US FDA has granted BTD to Olorofim for the treatment of CNS Valley Fever (coccidioidomycosis)
• The therapy is currently being evaluated in P-IIb study in patients with coccidioidomycosis with proven IFD or probable IA and either refractory disease, resistance, or intolerance to available agents
• The BTD follows the previous BTD that was granted on Nov 11, 2019, for the treatment of invasive mold infections in patients with limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, and infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: F2G